Search Results - "Talebian, Vida"

The GRHL2/ZEB Feedback Loop—A Key Axis in the Regulation of EMT in Breast Cancer by Mooney, Steven M., Talebian, Vida, Jolly, Mohit Kumar, Jia, Dongya, Gromala, Monica, Levine, Herbert, McConkey, Brendan J.

“…ABSTRACT More than 90% of cancer‐related deaths are caused by metastasis. Epithelial‐to‐Mesenchymal Transition (EMT) causes tumor cell dissemination while the…”
Get full text

Abstract 1222: Validating the WD repeat protein CDC40 as a potential therapeutic target for lung cancer by Hu, Die, Thériault, Brigitte L., Talebian, Vida, Owen, Julie, Marcellus, Richard, Al-awar, Rima

“…Lung cancer is the most lethal cancer globally, accounting for 1.8 million deaths in 2018. Presently, there is a need for novel targets for the development of…”
Get full text

Abstract 2701: Molecular profiling to assess the immune response to neoadjuvant SABR in early breast cancer by Spears, Melanie, Talebian, Vida, Liao, Linda, Hopkins, Megan, Lynn, Kalan, Lock, Michael, Kornecki, Anat, Bartlett, John M., Brackstone, Muriel

“…Radiation therapy is used successfully in the treatment of breast cancer. Stereotactic radiation therapy (SBRT) is well established in the treatment of lung…”
Get full text

Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial by Spears, Melanie, Hopkins, Megan, Keyhanian, Kianoosh, Robertson, Susan, Liao, Linda, Talebian, Vida, Awan, Arif Ali, Pond, Gregory Russell, Bartlett, John, Bender, Lewis H., Walters, Ian B., Lopez-Ozuna, Vanessa, Arnaout, Angel

“…573 Background: Most breast cancers are considered immunological cold and are therefore minimally responsive to immunotherapies. Local cytotoxic therapies can…”
Get full text

Abstract 2726: Characterization of immune microenvironment and heterogeneity in breast cancer subtypes by Jain, Drashti, Liao, Linda, Hopkins, Megan, Quintayo, Mary Anne, Talebian, Vida, Bayani, Jane, Cheung, Alison, Yaffe, Martin, Bartlett, John, Spears, Melanie

“…Despite ongoing advancements in the clinical management of breast cancer (BC), the variability in the response to treatment requires continued understanding of…”
Get full text

Abstract 2698: Spatial gene expression profiling in breast cancer by Spears, Melanie, Talebian, Vida, Liao, Linda, Hopkins, Megan, Jain, Drashti, Quintayo, Mary Anne, Bayani, Jane, Cheung, Alison, Yaffe, Martin, Bartlett, John M.

“…Over the last decade breast cancer survival has improved, largely due to the therapies offered to patients with the disease. However, despite the advances in…”
Get full text

The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer: GRHL2-ZEB A XIS IN B REAST C ANCER by Mooney, Steven M., Talebian, Vida, Jolly, Mohit Kumar, Jia, Dongya, Gromala, Monica, Levine, Herbert, McConkey, Brendan J.

Get full text

Abstract 4416: Rapid, low-input, targeted NGS workflow for DNA methylation by Pickle, Loni, Hatch, Andrew, Yavas, Gokhan, Spears, Melanie, Gasparini, Louis, Talebian, Vida, Lee, Anna Ying-Wah, Lariviere, Mathieu, Bayani, Jane, Sadis, Seth, Smith, Jeffrey M.

“…DNA methylation is a fundamental epigenetic process that regulates human gene expression. In cancer, methylation changes promote proliferation networks and…”
Get full text

Abstract PS16-03: Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study – the INVINCIBLE Trial by Arnaout, Angel, Bender, Lewis, Hopkins, Megan, Ozuna, Vanessa Lopez, Liao, Linda, Robertson, Susan, Talebian, Vida, Keyhanian, Kianoosh, Awan, Arif, Abbate, Franco, Walters, Ian, Pond, Gregory, Bartlett, John, Radvanyi, Lazlo, Spears, Melanie

“…Background: Larger tumors pose an increased risk for breast cancer (BC) recurrence post-surgery. In addition, most BC outside of the triple negative subtype…”
Get full text

Abstract PD11-02: PD11-02 A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 in Early Stage Breast Cancer: the INVINCIBLE Trial by Arnaout, Angel, Robertson, Susan, Keyhanian, Kianoosh, Hopkins, Megan, Liao, Linda, Talebian, Vida, Awan, Arif, Bartlett, John MS, Pond, Gregory R., Radvanyi, Lazlo, Bender, Lewis H., Walters, Ian B., Ozuna, Vanessa Lopez, Spears, Melanie

“…Background: The majority of breast cancers outside of the triple negative subtype are considered immunological quiescent and are therefore minimally responsive…”
Get full text